Comparison of myofibroblasts expression in oral squamous cell carcinoma, verrucous carcinoma, high risk epithelial dysplasia, low risk epithelial dysplasia and normal oral mucosa

Author(s): Chaudhary M, Gadbail AR, Vidhale G, MankarGadbail MP, Gondivkar SM, et al.


The aim was to evaluate and compare the presence of myofibroblasts in oral squamous cell carcinoma (OSCC), verrucous carcinoma (VC), high-risk epithelial dysplasia (HRED), low-risk epithelial dysplasia (LRED), and normal oral mucosa (NOM). The study consisted of 37 OSCC, 15 VC, 15 HRED, 15 LRED and 15 NOM. α-smooth muscle actin (α-SMA) antibody was used to identify myofibroblasts. The α-SMA expression was not observed in NOM and LRED. The α-SMA was expressed in 97.29% of OSCC, 86.66% of VC, 46.66 % of HRED. The α-SMA expression was significantly higher in OSCC than VC (p = 0.023) and HRED (p < 0.000). The α-SMA expression was significantly higher in VC than HRED (p = 0.043). Myofibroblastic expression, as highlighted by α-SMA, is undetectable in NOM and LRED but increases as the disease progresses from potentially malignant disorders, as HRED to VC to invasive OSCC. Thus, proliferation of myofibroblasts may be used as a stromal marker of oral premalignancy and malignancy.

Similar Articles

Osteonectin, a bone-specific protein linking mineral to collagen

Author(s): Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, et al.

Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma

Author(s): Mantoni TS, Schendel RR, Rödel F, Niedobitek G, Al-Assar O, et al.

Frequent inactivation of SPARC by promoter hypermethylation in colon cancers

Author(s): Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, et al.

Fibroblasts in cancer

Author(s): Kalluri R, Zeisberg M

CD34+ fibrocytes in neoplastic and inflammatory pancreatic lesions

Author(s): Barth PJ, Ebrahimsade S, Hellinger A, Moll R, Ramaswamy A